Please wait while the formulary information is being retrieved.
TECVAYLI (teclistamab-cqyv)
- multiple myeloma
10 mg/mL subcutaneous solution
- Dosage information is not available
90 mg/mL subcutaneous solution
- Dosage information is not available
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactation
Contraindicated
- Abnormal hepatic function tests
- Anemia
- Hyperbilirubinemia
- Neutropenic disorder
- Pregnancy
- Severe infection
- Thrombocytopenic disorder
Severe
Moderate
- None
TECVAYLI (teclistamab-cqyv)
- multiple myeloma
- Anemia
- Cytokine release syndrome
- Hypotension
- Immune effector cell-associated neurotoxicity syndrome
- Infection
- Leukopenia
- Lymphopenia
- Neutropenic disorder
- Pneumonia
- Thrombocytopenic disorder
- Diarrhea
- Fatigue
- Fever
- Injection site sequelae
- Musculoskeletal pain
- Nausea
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Cardiac arrhythmia
- Encephalopathy
- Hemorrhage
- Hyperbilirubinemia
- Hypertension
- Hypogammaglobulinemia
- Hypoxia
- Increased aspartate transaminase
- Kidney disease with reduction in GFR
- Anorexia
- Bone pain
- Constipation
- Cough
- Edema
- Gait abnormality
- Headache disorder
- Pain
- Peripheral sensory neuropathy
- Urinary tract infection
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Teclistamab-cqyv
Safety and efficacy not established in pediatric patients.
- 1 Day – 18 Years
- Safety and efficacy not established in pediatric patients.
Teclistamab-cqyv
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible
Contraindicated
Teclistamab-cqyv
Mfr recommends to avoid during tx and for 5 months after the last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr recommends to avoid during tx and for 5 months after the last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may cause a serious (even fatal) reaction called cytokine release syndrome-CRS. Careful monitoring and prompt treatment may decrease your risk. Before treatment with this medication, tell your doctor your medical history, especially of any current/recent infection.<br /><br />Tell your doctor right away if you have any symptoms of CRS such as high fever, trouble breathing, chills, dizziness/lightheadedness, fast heartbeat, confusion, or headache. Teclistamab can cause serious nervous system problems. Tell your doctor right away if you have any symptoms such as headache, trouble speaking, shaking, jerking movements, numbness/tingling, muscle spasms, changes in your handwriting, double vision, problems walking, muscle weakness in your body or face, hearing loss, or burning/throbbing/stabbing pain.<br /><br /> To receive this medication in the United States, you must understand, agree to, and carefully follow the requirements of the Tecvayli REMS Program. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
| Multiple myeloma | |
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
| 0-9 | A-Z |
|---|---|
| C90.0 | Multiple myeloma |
| C90.00 | Multiple myeloma not having achieved remission |
| C90.02 | Multiple myeloma in relapse |
Formulary Reference Tool